Cargando…
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, the safety and efficacy data from five Phase 2 studies of tofacitinib in patients with RA are summarized. Tofacitinib 1–30 mg twice daily was investigated, as monotherapy and in combination with metho...
Autores principales: | Fleischmann, Roy, Kremer, Joel, Tanaka, Yoshiya, Gruben, David, Kanik, Keith, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie, Zwillich, Samuel H., Keystone, Edward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396326/ https://www.ncbi.nlm.nih.gov/pubmed/27451980 http://dx.doi.org/10.1111/1756-185X.12901 |
Ejemplares similares
-
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016) -
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2016) -
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
por: Strand, Vibeke, et al.
Publicado: (2015) -
Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
por: Strand, Vibeke, et al.
Publicado: (2017) -
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)